Quanta Pharma Tirzepatide 30mg Free BW

Included Free 3ml Bacteriostatic Water with order Janoshik Lab Verified Independent third-party testing 99.68% Purity 30.49mg Actual Content Verify at janoshik.com/verify using key: 38NQN8WMT3ZS | Tested: May 2025 Quanta Tirzepatide 30mg is a pharmaceutical-grade dual agonist peptide that activates both GLP-1 and GIP receptors. This lyophilized vial from Quanta Pharma offers researchers a high-purity compound for advanced studies in glycemic control, weight management, and metabolic health. Independently lab-verified at 99.68% purity. Available for UK delivery with fast dispatch. Tirzepatide 30mg Specifications Peptide Tirzepatide Type Dual Agonist Dosage 30mg/vial Purity 99.68% Form Lyophilized Half-Life ~5 days Tirzepatide 30mg by Quanta Pharma Tirzepatide Research Benefits Dual receptor action - Targets both GLP-1 and GIP receptors for comprehensive metabolic research Glycemic control - Researched for enhancing insulin secretion and decreasing glucagon levels Appetite regulation - Shows significant effects on hunger signalling and satiety pathways Weight management - Investigated for substantial effects on body composition and weight loss Extended half-life - Approximately 5 days allows for weekly administration in research protocols How Tirzepatide Works Tirzepatide is a dual agonist peptide that activates two key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action approach enhances insulin secretion while decreasing glucagon levels. By targeting both GLP-1 and GIP pathways simultaneously, Tirzepatide research has demonstrated significant potential for improved glycemic control and weight management. The extended half-life of approximately 5 days makes it particularly suitable for once-weekly research protocols. Tirzepatide vs Semaglutide While Semaglutide targets only the GLP-1 receptor, Tirzepatide activates both GLP-1 and GIP receptors for a dual-action approach. Research suggests this may offer enhanced effects in metabolic studies, making Tirzepatide a leading compound for laboratory investigation into obesity, type 2 diabetes, and metabolic syndrome. ⚠️ FOR LABORATORY RESEARCH USE ONLY NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE Safety Classification: - For use by qualified research personnel only - Keep detailed records of usage and storage as per UK research regulations Legal Notice: This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.